Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Trial of XH001 (Neoantigen Cancer Vaccine) Sequential Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Next Previous
Search
Trial Profile

Efficacy and Safety Trial of XH001 (Neoantigen Cancer Vaccine) Sequential Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Ipilimumab (Primary) ; XH 001 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Apr 2025 Planned number of patients changed from 12 to 24.
  • 04 Apr 2025 Status changed from not yet recruiting to recruiting.
  • 15 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top